Isotechnika Pharma Inc IPHAF

RE: Most of my info is on ISA website.

[labumba]

 
 

" What got me started digging when Phase 2b started was a simple question:  "Why are these guys comparing 247 to Tacrolimus when it seems they want to market it head to head with cyclosporin?"

I have always assumed that Foster et al may be arrogant but not stupid.  They started as academics themselves and that is one cut throat, backstabing world.  "

What is your implication ?
Are you saying Tacrolimus is superior than 247 in terms of  " acute rejection " ?  I think its still too early to conclude before the final results presented in the ATC.
Just a reminder,  every kind of parameter data includes its means and median numbers among all dosing groups as compiled in the intermin results.